Cargando…

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier

Recently, immune checkpoint inhibitors (ICIs) therapy has become a promising therapeutic strategy with encouraging therapeutic outcomes due to their durable anti-tumor effects. Though, tumor inherent or acquired resistance to ICIs accompanied with treatment-related toxicities hamper their clinical u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vafaei, Somayeh, Zekiy, Angelina O., Khanamir, Ramadhan Ado, Zaman, Burhan Abdullah, Ghayourvahdat, Arman, Azimizonuzi, Hannaneh, Zamani, Majid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725311/ https://www.ncbi.nlm.nih.gov/pubmed/34980128 http://dx.doi.org/10.1186/s12935-021-02407-8

Ejemplares similares

First study on molecular epidemiology of caseous lymphadenitis in slaughtered sheep and goats in Duhok Province, Iraq
por: Khanamir, Ramadhan Ado, et al.
Publicado: (2023)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
por: Tong, Justin, et al.
Publicado: (2022)

Impact of Diets on Response to Immune Checkpoint Inhibitors (ICIs) Therapy against Tumors
por: Zhang, Xin, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI) genes and aging in malignant melanoma patients: a clinicogenomic TCGA study
por: Safi, Mohammed, et al.
Publicado: (2022)

Predictive Biomarkers for Outcomes of Immune Checkpoint Inhibitors (ICIs) in Melanoma: A Systematic Review
por: Baltussen, Joosje C., et al.
Publicado: (2021)

ICI efficacy information portal: a knowledgebase for responder prediction to immune checkpoint inhibitors
por: Chen, Jiamin, et al.
Publicado: (2023)

Relation between ocular paraneoplastic syndromes and Immune Checkpoint Inhibitors (ICI): review of literature
por: Casselman, Pauline, et al.
Publicado: (2023)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

Immune checkpoint inhibitor (ICI) combination therapy compared to monotherapy in advanced solid cancer: A systematic review
por: Ma, Xiaoting, et al.
Publicado: (2021)

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images
por: Liberini, Virginia, et al.
Publicado: (2021)

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy
por: Shi, Congqi, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment
por: Okuno, Takae, et al.
Publicado: (2022)

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
por: Torasawa, Masahiro, et al.
Publicado: (2023)

A novel nomogram and prognostic factor for metastatic renal cell carcinoma survival in the era of immune checkpoint inhibitors (ICIs)
por: Alradhi, Mohammed, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor (ICI) Genes and Aging in Clear Cell Renal Cell Carcinoma (ccRCC): Clinical and Genomic Study
por: Al-Danakh, Abdullah, et al.
Publicado: (2022)

Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability
por: Borelli, Beatrice, et al.
Publicado: (2022)

Stereotactic Body Radiation Therapy (SBRT) Plus Immune Checkpoint Inhibitors (ICI) in Hepatocellular Carcinoma and Cholangiocarcinoma
por: Jiang, Joanna, et al.
Publicado: (2022)

Efficacy and safety of immune checkpoint inhibitors (ICIs) combined with antiangiogenic therapy for thymic epithelial tumors (TETs): a retrospective study
por: Xiang, Jing, et al.
Publicado: (2023)

Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC
por: Dong, Yawen, et al.
Publicado: (2021)

Alveolar Hemorrhage Caused by the Combination of Immune Checkpoint Inhibitors (ICIs) and Angiogenesis Inhibitors: The Underlying Long-Term Vascular Endothelial Growth Factor (VEGF) Inhibition
por: Shijubou, Naoki, et al.
Publicado: (2022)

Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
por: Shah, Neil J., et al.
Publicado: (2019)

Recognizing Prognostic and Predictive Biomarkers in the Treatment of Non-Small Cell Lung Cancer (NSCLC) with Immune Checkpoint Inhibitors (ICIs)
por: Giustini, Nicholas, et al.
Publicado: (2021)

Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort
por: D’Aiello, Angelica, et al.
Publicado: (2021)

Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
por: Albandar, Heidar J., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?
por: Modena, Alessandra, et al.
Publicado: (2016)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
por: Brueckl, Wolfgang M., et al.
Publicado: (2020)

Occurrence of Possible Rheumatologic Immune-Related Adverse Events (rh-irAEs) Associated with Immune Checkpoint Inhibitor (ICI) Therapy
por: Anjohrin, Suzanne, et al.
Publicado: (2021)

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired
por: Marei, Hany E., et al.
Publicado: (2023)

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature
por: Yadav, Ruchi, et al.
Publicado: (2023)

ICIS05 CONFERENCE
por: Lau, C, et al.
Publicado: (02/1)

The Icy Realm of the Rime
por: Potter, Polyxeni
Publicado: (2011)

Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM
por: Zhang, Wenjing, et al.
Publicado: (2023)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
por: Daban, A, et al.
Publicado: (2023)

Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients’ Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC)
por: Nardin, Charlée, et al.
Publicado: (2023)

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
por: Simonaggio, Audrey, et al.
Publicado: (2021)

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients
por: Chalker, Cameron, et al.
Publicado: (2022)

Enceladus and the icy moons of Saturn
por: Schenk, Paul M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f73sk4ial50e40jnpilf66b1i7